tofacitinib (3S Bio)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Nametofacitinib (3S Bio)
Drug Alias NametofacitinibSSS-32
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK3Tyrosine-protein kinase JAK1
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator Companies3sbio Inc
China Registration ClassN/A

Develop Information

Active Companies3sbio Inc
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A